S3 Connected Health, Dublin, Ireland.
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons (RCSI), University of Medicine and Health Sciences, Dublin, Ireland.
Adv Ther. 2023 May;40(5):2457-2470. doi: 10.1007/s12325-023-02496-z. Epub 2023 Apr 5.
Vosoritide is the first approved pharmacological treatment for achondroplasia and is indicated for at-home injectable administration by a trained caregiver. This research aimed to explore parents' and children's experience of initiating vosoritide and administering this treatment at home.
Qualitative telephone interviews were conducted with parents of children being treated with vosoritide in France and Germany. Interviews were transcribed and analysed using thematic analysis.
Fifteen parents participated in telephone interviews in September and October 2022. The median age of children in this sample was 8 years old (range 3-13 years) and children had been taking treatment from 6 weeks to 13 months. Four themes document families' experience with vosoritide: (1) awareness of vosoritide treatment, uncovering that parents first heard of vosoritide through their own research, patient advocacy groups, or through their physicians; (2) treatment understanding and decision-making, which found that their decision to take treatment is based on a desire to relieve future medical complications and increase height for improved independence, and they consider the extent to which the treatment has severe side effects; (3) training and initiation, which showed that the hospital initiation and training sessions varied considerably both across and within countries, with different treatment centres taking different approaches; and (4) managing treatment at home brings psychological and practical challenges, which are ultimately overcome with perseverance and available support.
Parents and children are resilient to challenges posed by a daily injectable treatment and highly motivated to improve their quality of life. Parents are prepared to overcome short-term treatment challenges for future gains in terms of health and functional independence for their children. Greater support could ensure they have the right information to initiate treatment and manage treatment at home, which will improve parents' and children's experience.
Vosoritide 是首个获批用于治疗软骨发育不全症的药物疗法,适用于经过培训的护理人员在家中进行注射。本研究旨在探讨父母在为子女启动 vosoritide 治疗并在家中进行治疗管理时的体验。
我们对正在法国和德国接受 vosoritide 治疗的儿童的父母进行了定性电话访谈。访谈内容转录后,采用主题分析法进行分析。
2022 年 9 月至 10 月期间,15 名父母接受了电话访谈。该样本中儿童的中位年龄为 8 岁(范围 3-13 岁),接受治疗的时间为 6 周至 13 个月。有 4 个主题记录了家庭使用 vosoritide 的体验:(1)对 vosoritide 治疗的认识,父母最初是通过自己的研究、患者权益组织或医生了解到 vosoritide;(2)治疗的理解和决策,他们决定接受治疗是为了缓解未来的医疗并发症并增加身高以提高独立性,并考虑治疗的严重副作用程度;(3)培训和启动,结果表明,医院的启动和培训课程在国家之间和国家内部差异很大,不同的治疗中心采取不同的方法;(4)在家管理治疗带来心理和实际挑战,但最终通过坚持和可获得的支持克服了这些挑战。
父母和子女能够应对日常注射治疗带来的挑战,并对提高生活质量有强烈的意愿。父母愿意克服短期治疗挑战,以换取子女在健康和功能独立性方面的未来获益。更多的支持可以确保他们获得启动治疗和在家管理治疗所需的正确信息,从而改善父母和子女的体验。